ETFMG Treatments Testing and Advancements ETF (GERM)
| Assets | $12.48M |
| Expense Ratio | 0.68% |
| PE Ratio | 6.94 |
| Shares Out | n/a |
| Dividend (ttm) | $0.22 |
| Dividend Yield | 1.22% |
| Ex-Dividend Date | Sep 20, 2023 |
| Payout Ratio | 8.49% |
| 1-Year Return | -25.26% |
| Volume | 1,285 |
| Open | 17.56 |
| Previous Close | 17.63 |
| Day's Range | 17.57 - 17.86 |
| 52-Week Low | 15.67 |
| 52-Week High | 25.07 |
| Beta | n/a |
| Holdings | 63 |
| Inception Date | Jun 17, 2020 |
About GERM
Fund Home PageThe ETFMG Treatments Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is issued by ETFMG.
Top 10 Holdings
50.43% of assets| Name | Symbol | Weight |
|---|---|---|
| Quest Diagnostics Incorporated | DGX | 6.91% |
| Laboratory Corporation of America Holdings | LH | 6.90% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 5.63% |
| BioNTech SE | BNTX | 5.50% |
| Zai Lab Limited | ZLAB | 4.73% |
| Moderna, Inc. | MRNA | 4.55% |
| Vaxcyte, Inc. | PCVX | 4.40% |
| Immunocore Holdings plc | IMCR | 4.13% |
| Dynavax Technologies Corporation | DVAX | 3.93% |
| ImmunityBio, Inc. | IBRX | 3.76% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 20, 2023 | $0.040 | Sep 22, 2023 |
| Jun 21, 2023 | $0.060 | Jun 23, 2023 |
| Mar 22, 2023 | $0.090 | Mar 24, 2023 |
| Dec 28, 2022 | $0.0286 | Dec 30, 2022 |
| Sep 21, 2022 | $0.060 | Sep 23, 2022 |
| Jun 22, 2022 | $0.050 | Jun 24, 2022 |
News
Amplify's Christian Magoon on Purchase of ETFMG's ETFs
In June, the ETF industry learned that issuer ETF Managers Group would be selling its funds to Amplify ETFs. The transaction, once completed, will bring Amplify's total AUM to $8 billion invested acro...
This Week in ETFs: A Summer Slowdown
The week ending Friday, July 21, has been busy for the ETF industry, though launches were muted. A total of seven funds rolled out, which suggests the market could be entering some kind of summer slum...
Biotech ETFs Slip After Novavax Cuts 2022 Guidance
Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Gen...
Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs
Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in i...
China ETFs Drop On Audit Enforcement
The first tranche of Chinese ADRs affected by a 2020 law has been released.
COVID Biotech ETFs Rise At Fever Pace
ETFs that look at a subsector of biotech have significantly outperformed broader biotech funds this year.
Biotech ETFs extend January gains
Biotech exchange-traded funds rallied Monday as investors continued to monitor the sector and its impact on the coronavirus pandemic. The ETFMG Treatments Testing and Advancement ETF gained 4.6% mid-m...
First Vaccine ETF Should See Halcyon Days Ahead
There was big news on the coronavirus vaccine front Monday when Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) said their vaccine delivered an impressive showing in Phase 3 trials. What Happened: Alon...
Investing in coronavirus themed ETFs which focus on companies involved in testing and treatment
ETF Managers Group CEO Sam Masucci discusses GERM an ETF that invests in companies that are focused on COVID-19 treatment and testing.
ETF Open To Close Ratio Jumps
An unusually high number of launches in June boosted the open-to-close ratio.
Novavax's 30% surge boosts biotech ETFs to best day in weeks
Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.
New Pharma ETF Focuses on Testing and Treatment for Infectious Diseases—but Not Covid-19
The newest health care exchange-traded fund is unique in that three stalwarts of other industry funds aren’t even among its top holdings.